Crescent Biopharma Q2 FY26 net loss widens to $24.8 million

Reuters2026/07/30 11:49

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Crescent Biopharma posted a GAAP net loss of USD 24.8 million for Q2 2026, or USD 0.74 per share, versus a loss of USD 21.8 million.
RD expense rose to USD 19.4 million from USD 12.1 million, driven by higher CMC and clinical activity costs plus personnel-related costs.
Cash and cash equivalents were USD 171.6 million; pro forma cash was USD 305.1 million including USD 133.5 million net proceeds from July’s offering.
Completed a USD 143.7 million public offering; Crescent expects cash to fund operations into the second half of 2028.
ASCEND Phase 1/2 trial of CR-001 continued enrolling globally; proof-of-concept data expected in Q1 2027, with additional combination readouts targeted mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-050805), on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Crescent Biopharma Q2 FY26 net loss widens to $24.8 million

You may also like

Crypto prices